Short answer
Scholar Rock Holding Corp (SRRK) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$110M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$110M
- +0.1% YoY · −4.2% QoQ
- EPS (diluted)
- −$0.84
- +14.3% YoY · −1.2% QoQ
Source: XBRL data from the Scholar Rock Holding Corp (SRRK) Q2 2026 10-Q on SEC EDGAR. USD.
Scholar Rock Holding Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- FDA CRL triggered by third-party fill-finish facility inspection observations; BLA resubmitted March 2026 with September 30, 2026 PDUFA date
- EMA approval risk from FDA OAI classification and GMP noncompliance, potentially causing delayed review or negative CHMP opinion
- FDA staffing and resource reductions in 2025 threaten timely review of the accepted BLA resubmission
- Commercialization risk from limited sales, distribution, marketing, and market-access capabilities ahead of potential U.S. and European launch
- Capital requirement risk from continuing net losses and need for additional funding to complete development and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Scholar Rock Holding Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.